Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020

Abstract The 2020 update of the Canadian Stroke Best Practice Recommendations (CSBPR) for the Secondary Prevention of Stroke includes current evidence-based recommendations and expert opinions intended for use by clinicians across a broad range of settings. They provide guidance for the prevention of ischemic stroke recurrence through the identification and management of modifiable vascular risk factors. Recommendations address triage, diagnostic testing, lifestyle behaviors, vaping, hypertension, hyperlipidemia, diabetes, atrial fibrillation, other cardiac conditions, antiplatelet and anticoagulant therapies, and carotid and vertebral artery disease. This update of the previous 2017 guideline contains several new or revised recommendations. Recommendations regarding triage and initial assessment of acute transient ischemic attack (TIA) and minor stroke have been simplified, and selected aspects of the etiological stroke workup are revised. Updated treatment recommendations based on new evidence have been made for dual antiplatelet therapy for TIA and minor stroke; anticoagulant therapy for atrial fibrillation; embolic strokes of undetermined source; low-density lipoprotein lowering; hypertriglyceridemia; diabetes treatment; and patent foramen ovale management. A new section has been added to provide practical guidance regarding temporary interruption of antithrombotic therapy for surgical procedures. Cancer-associated ischemic stroke is addressed. A section on virtual care delivery of secondary stroke prevention services in included to highlight a shifting paradigm of care delivery made more urgent by the global pandemic. In addition, where appropriate, sex differences as they pertain to treatments have been addressed. The CSBPR include supporting materials such as implementation resources to facilitate the adoption of evidence into practice and performance measures to enable monitoring of uptake and effectiveness of recommendations.

[1]  A. Beiser,et al.  Incidence of Transient Ischemic Attack and Association With Long-term Risk of Stroke. , 2021, JAMA.

[2]  A. Demchuk,et al.  Global impact of COVID-19 on stroke care , 2021, International journal of stroke : official journal of the International Stroke Society.

[3]  L. Leocani,et al.  Stroke and digital technology: a wake-up call from COVID-19 pandemic , 2021, Neurological Sciences.

[4]  A. Demchuk,et al.  Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin , 2020, Stroke.

[5]  G. Gore,et al.  Frequency and predictors of occult cancer in ischemic stroke: A systematic review and meta-analysis , 2020, International journal of stroke : official journal of the International Stroke Society.

[6]  R. Lopes,et al.  Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. , 2020, The New England journal of medicine.

[7]  Eric E. Smith,et al.  Canadian stroke best practice recommendations: Management of Spontaneous Intracerebral Hemorrhage, 7th Edition Update 2020 , 2020, International journal of stroke : official journal of the International Stroke Society.

[8]  J. Healey,et al.  The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. , 2020, The Canadian journal of cardiology.

[9]  C. Cannon,et al.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.

[10]  K. Bailey,et al.  Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. , 2020, JAMA.

[11]  S. Johnston,et al.  Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. , 2020, The New England journal of medicine.

[12]  S. Johnston,et al.  Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial , 2020, Stroke.

[13]  R. Swartz,et al.  Call 911: Lower Ambulance Utilization Among Young Adults, Especially Women, with Stroke , 2020, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[14]  Lawrence A Leiter,et al.  Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. , 2020, The Canadian journal of cardiology.

[15]  B. Hill.  The COVID-19 pandemic. , 2020, British journal of nursing.

[16]  Eric E. Smith,et al.  Canadian Stroke Best Practice Guidance During the COVID-19 Pandemic , 2020, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[17]  M. Schermerhorn,et al.  Clinical impact of sex on carotid revascularization. , 2020, Journal of vascular surgery.

[18]  Eric E. Smith,et al.  People With Lived Experience at the Centre of Canadian Stroke Best Practice Recommendations: A Model for Guideline Developers , 2020, Journal of patient experience.

[19]  R. de Caterina,et al.  Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. , 2019, The New England journal of medicine.

[20]  S. Johnston,et al.  Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. , 2019, JAMA neurology.

[21]  H. Crijns,et al.  Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration. , 2019, Circulation.

[22]  E. Vicaut,et al.  A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. , 2019, The New England journal of medicine.

[23]  J. Douketis,et al.  Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. , 2019, JAMA internal medicine.

[24]  K. Shimada,et al.  Effect of Standard vs Intensive Blood Pressure Control on the Risk of Recurrent Stroke: A Randomized Clinical Trial and Meta-analysis. , 2019, JAMA neurology.

[25]  N. Hagiwara,et al.  Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. , 2019, The New England journal of medicine.

[26]  É. Marijon,et al.  Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology. , 2019, Archives of Cardiovascular Diseases.

[27]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[28]  W. E. Sanabria,et al.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial , 2019, The Lancet.

[29]  Thalia Shoshana Field,et al.  Who says “no” to participating in stroke clinical trials and why: an observational study from the Vancouver Stroke Program , 2019, Trials.

[30]  R. Sacco,et al.  Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source , 2019, The New England journal of medicine.

[31]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[32]  E. Ringelstein,et al.  Angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy compared to best medical treatment: One-year interim results of SPACE-2 , 2019, International journal of stroke : official journal of the International Stroke Society.

[33]  Gyeong-Moon Kim,et al.  The Long-Term Effect of Cancer on Incident Stroke: A Nationwide Population-Based Cohort Study in Korea , 2019, Front. Neurol..

[34]  Katie Myers Smith,et al.  A Randomized Trial of E‐Cigarettes versus Nicotine‐Replacement Therapy , 2019, The New England journal of medicine.

[35]  M. Pencina,et al.  Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial , 2019, JAMA.

[36]  I. Nemec.  Dabigatran for Prevention of Stroke After Embolic Stroke of Undetermined Source , 2019 .

[37]  T. Vilsbøll,et al.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2019, The New England journal of medicine.

[38]  G. Guyatt,et al.  Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis , 2018, British medical journal.

[39]  J. Cleland,et al.  Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease , 2018, The New England journal of medicine.

[40]  G. Chatellier,et al.  Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta‐Analysis, and New Insights From the CLOSE Study , 2018, Journal of the American Heart Association.

[41]  J. Saver,et al.  Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Ischemic Stroke: A Topical Review , 2018, Stroke.

[42]  Thalia Shoshana Field,et al.  Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017 , 2018, International journal of stroke : official journal of the International Stroke Society.

[43]  Seung‐Jung Park,et al.  Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial. , 2018, Journal of the American College of Cardiology.

[44]  R. Conwit,et al.  Clopidogrel and Aspirin in Acute Ischemic Stroke and High‐Risk TIA , 2018, The New England journal of medicine.

[45]  Deepak L. Bhatt,et al.  Stroke Outcomes in the Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) Trial , 2018 .

[46]  H. Kamel,et al.  Risk of Arterial Thromboembolism in Patients With Cancer. , 2017, Journal of the American College of Cardiology.

[47]  W. Feng,et al.  Mobile health as a viable strategy to enhance stroke risk factor control: A systematic review and meta-analysis , 2017, Journal of the Neurological Sciences.

[48]  M. Brouwers,et al.  Reporting Items for Updated Clinical Guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp) , 2017, PLoS medicine.

[49]  S. Yusuf,et al.  Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study , 2016, The Lancet.

[50]  C. Viscoli,et al.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.

[51]  Ivy Shiue,et al.  Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2016, The Lancet Neurology.

[52]  S. Johnston,et al.  Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. , 2016, JAMA.

[53]  T. Fahey,et al.  Telehealth for patients at high risk of cardiovascular disease: pragmatic randomised controlled trial , 2016, British Medical Journal.

[54]  S. Anker,et al.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.

[55]  Thalia Shoshana Field,et al.  Rapid Assessment and Treatment of Transient Ischemic Attacks and Minor Stroke in Canadian Emergency Departments: Time for a Paradigm Shift. , 2015, Stroke.

[56]  Eric E. Smith,et al.  Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Guidelines, Update 2014 , 2015, International journal of stroke : official journal of the International Stroke Society.

[57]  L. Lerman,et al.  Digital health interventions for the prevention of cardiovascular disease: a systematic review and meta-analysis. , 2015, Mayo Clinic proceedings.

[58]  Andrew E. Hanselman,et al.  Topical Review , 2015, Foot & ankle specialist.

[59]  S. Connolly,et al.  Embolic strokes of undetermined source: the case for a new clinical construct , 2014, The Lancet Neurology.

[60]  A. Mounsey,et al.  Clinical inquiry: Do oral contraceptives carry a significant risk of stroke for women with migraines? , 2013, The Journal of family practice.

[61]  P. Gorelick,et al.  Early Dual Versus Mono Antiplatelet Therapy for Acute Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack , 2022 .

[62]  G. Lip,et al.  Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure in Sinus Rhythm: A Subgroup Analysis of WARCEF, a Randomized Controlled Trial , 2013, Circulation. Heart failure.

[63]  Shunichi Homma,et al.  Warfarin and aspirin in patients with heart failure and sinus rhythm. , 2012, The New England journal of medicine.

[64]  Michelle E. Kho,et al.  AGREE II: advancing guideline development, reporting and evaluation in health care , 2010, Canadian Medical Association Journal.

[65]  Gene Feder,et al.  AGREE II: advancing guideline development, reporting and evaluation in health care. , 2010, Journal of clinical epidemiology.

[66]  The Emerging Risk Factors Collaboration.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.

[67]  N J Wald,et al.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.

[68]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[69]  M. Law.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009 .

[70]  S. Schinner.  Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes , 2009 .

[71]  S. Schinner,et al.  Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[72]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[73]  A. Demchuk,et al.  Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial , 2007, The Lancet Neurology.

[74]  S. Gutnikov,et al.  Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison , 2007, The Lancet.

[75]  H. Koennecke.  Secondary Prevention of Stroke , 2004, CNS drugs.

[76]  G. Lip,et al.  Antithrombotic therapy for atrial fibrillation , 2002, BMJ : British Medical Journal.

[77]  M. Harrison,et al.  Facilitating the use of evidence in practice: evaluating and adapting clinical practice guidelines for local use by health care organizations. , 2002, Journal of obstetric, gynecologic, and neonatal nursing : JOGNN.

[78]  北村 聖.  "The New England Journal of Medicine". , 1962, British medical journal.